1.77
+0.09(+5.36%)
Currency In USD
| Previous Close | 1.68 |
| Open | 1.7 |
| Day High | 1.78 |
| Day Low | 1.7 |
| 52-Week High | 9.25 |
| 52-Week Low | 0.87 |
| Volume | 180,981 |
| Average Volume | 541,806 |
| Market Cap | 75.85M |
| PE | 0.43 |
| EPS | 4.09 |
| Moving Average 50 Days | 1.65 |
| Moving Average 200 Days | 2.88 |
| Change | 0.09 |
If you invested $1000 in Outlook Therapeutics, Inc. (OTLK) since IPO date, it would be worth $2.59 as of June 25, 2025 at a share price of $1.77. Whereas If you bought $1000 worth of Outlook Therapeutics, Inc. (OTLK) shares 5 years ago, it would be worth $62.77 as of June 25, 2025 at a share price of $1.77.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event
GlobeNewswire Inc.
Jun 18, 2025 1:05 PM GMT
Live webcast on Wednesday, June 25th at 12:00 PM ETISELIN, N.J., June 18, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of
Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
GlobeNewswire Inc.
Jun 10, 2025 12:05 PM GMT
ISELIN, N.J., June 10, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the Scottish Medi
Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD
GlobeNewswire Inc.
Jun 02, 2025 11:00 AM GMT
LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK)2.8 million injections of repackaged off-label bevacizumab in Europe each year1 ISELIN, N.J.